Evidence map›Paper›PMID 28497806›Full record

ReviewNature reviews. Neurology2017

Management of diffuse low-grade gliomas in adults - use of molecular diagnostics.

Jan Buckner, Caterina Giannini, Jeanette Eckel-Passow, Daniel Lachance, Ian Parney, Nadia Laack, Robert Jenkins

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Benign Glioma.Advances in experimental medicine and biology · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Construction of ceRNA networks with different types ofAnnals of translational medicine · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. A Qualitative Signature to IdentifyFrontiers in molecular biosciences · 2022
    Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jan BucknerDivision of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Caterina GianniniDivision of Anatomic Pathology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Jeanette Eckel-PassowDivision of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Daniel LachanceDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Ian ParneyDepartment of Neurosurgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Nadia LaackDepartment of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Robert JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse WHO grade II gliomas are histologically and genetically heterogeneous. The 2016 WHO classification redefines grade II gliomas with respect to morphological and molecular tumour alterations: grade II oligodendrogliomas are defined by the presence of whole-arm codeletion in chromosomal arms 1p/19q, whereas isocitrate dehydrogenase (IDH) mutations define subclasses of astrocytoma. Although histological grade remains useful, the prognoses of patients with glioma are more tightly associated with molecular alterations than with grade, and chromosomal and gene array technologies are becoming increasingly beneficial in understanding tumour genetic heterogeneity. The indolent nature of the disease often creates subtle neurological symptoms that can be overlooked or misunderstood, resulting in delayed diagnosis. Seizures often herald the diagnosis, especially in patients who have IDH mutations, which are associated with an increased production of 2-hydroxyglutarate. Treatment paradigms have shifted, owing to new diagnostic criteria and new clinical trial evidence. Patients benefit more from chemoradiation than radiation alone, especially those with tumour IDH1 Arg132His mutations; gross total resection of the tumour, including tumours with IDH mutations, is associated with prolonged survival. Initial observation remains appropriate in patients whose rate of disease growth is not yet completely defined; such patients could include those with completely resected disease and those with 1p/19q codeleted tumours.

Indexed as

Brain NeoplasmsGliomaRadiotherapyAntineoplastic Agents, AlkylatingHumansIsocitrate DehydrogenasePathology, MolecularAntineoplastic Agents, AlkylatingIsocitrate Dehydrogenase

Identifiers

PMID28497806
OpenAlexW2612801846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.